Abstract
Objective: The aim of the present work was to develop new solid pharmaceutical delivery systems of mesalazine (5-aminosalicylic acid, 5-ASA) for its colon targeted release.
 Methods: Four different types of tablets of the same consistency (matrix and three-layered, with 5-ASA and dextran or pectin as excipients) were placed in a hard gelatin capsule. The 5-ASA release behavior from these formulations was compared to the release of the commercially available Asalazin® in three pH aqueous media in the presence of enzymes.
 Results: The produced tablet formulations conformed to the Pharmacopoeia standards. The results showed delayed-release (<10%) during the first two hours, in acidic media (pH 1.5), and modified-release thereafter (pH 6 and 7.4). When dextran was used, the drug release showed more extended-release characteristics, in comparison to pectin formulations, due to the formation of a thicker hydrogel.
 Conclusion: The new dosage forms could serve as a per os administration alternative dosage form for the delayed release of mesalazine to the colon
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
